Katexco was Founded by Prof Lawrence Steinman and Dr Jonathan Rothbard, who in Stanford developed over 26 medical research manuscripts together over the course of their careers and both of which have immense immunological therapy expertise. Prof Steinman’s research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is considered the most effective treatment for patients with multiple sclerosis and Crohn’s Disease. Moreover, the company’s Co-Founding, Prof Sir Marc Feldmann, discovered one of the most important discoveries of modern science and medicine, Anti-TNF therapy (the largest selling drug class globally) to treat inflammatory conditions such as Rheumatoid Arthritis.
Katexco is leveraging their pioneering experience in immunology to research and create orally active and available anti-inflammatory medicines.
Prof Lawrence Steinman and Dr Jonathan Rothbard conducted first Stanford Medical School Collaboration.
Prof Sir Marc Feldman and Dr Jonathan Rothbard’s first scientific collaboration. read more >
Dr Jonathan Rothbard and Prof Sir Marc Feldman’s first collaboration on molecular immunology at the Imperial Cancer Research Fund in London.
Prof Lawrence Steinman first showed critical molecule that led to Tysabri®. read more >
In collaboration between academia and biotechnology, Prof Lawrence Steinman and his team showed that α4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain.
The development of Prof Sir Marc Feldmann’s hypothesis translates into first successful clinical trials. read more >
The first of a series of successful clinical trials was performed in 1992, at Charing Cross Hospital, using an antibody, Infliximab (Prof Sir Marc Feldmann’s discovery) from Centocor.
Neurocrine Biosciences founded by Prof Lawrence Steinman in San Diego, California.
Prof Lawrence Steinman serves on the Board of Directors for Neurocrine Biosciences. It currently has a market capitalization on the NASDAQ of $9.1B USD. read more >
Neurocrine Biosciences is a San Diego, CA based biotechnology company that focuses on neurological, psychiatric and endocrine related disorders. Currently it has 3 late stage clinical programs, which is a novel achievement based on Prof Lawrence Steinman’s guidance.
Centocor acquired by Johnson and Johnson. read more >
Centocor is acquired by Johnson and Johnson for $4.9B USD. An acquisition largely lead by the underlying Intellectual Property developed by Prof Sir Marc Feldmann, notably Infliximab (later renamed Remicade). This is the company for which Prof Lawrence Steinman served on the Board of Directors.
Prof Lawrence Steinman wins the John M. Dystel Prize from the American Academy of Neurology and National MS Society. read more >
The Dystel Prize is sponsored by the American Academy of Neurology and the National Multiple Sclerosis Society. Steinman was recognized for his major contributions to our understanding of animal models of MS, and for his translating these findings to the clinical development of novel therapuetic strategies for MS.
Sir Marc Feldmann is awarded the Cameron Prize for Therapeutics by the University of Edinburgh. read more >
The Cameron Prize of the University of Edinburgh is awarded to a person who has made any highly important and valuable addition to Practical Therapeutics.